1 – 10 of 50
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2025
- 
                        Mark
        Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries–Comparisons to Matched Controls
    
    - Contribution to journal › Article
 
- 2024
- 
                        Mark
        Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
    
    - Contribution to journal › Article
 
- 2023
- 
                        Mark
        Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
    
    - Contribution to journal › Article
 
- 
                        Mark
        Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
    
    - Contribution to journal › Article
 
- 
                        Mark
        No difference in quality of life between persons with severe haemophilia A and B
    
    - Contribution to journal › Article
 
- 
                        Mark
        Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes
    (2023) In Lund University, Faculty of Medicine, Doctoral Dissertation Series- Thesis › Doctoral thesis (compilation)
 
- 2022
- 
                        Mark
        Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
    
    - Contribution to journal › Article
 
- 
                        Mark
        Long-term joint outcomes in adolescents with moderate or severe haemophilia A
    
    - Contribution to journal › Article
 
- 
                        Mark
        Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
    
    - Contribution to journal › Article
 
- 
                        Mark
        Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
    
    - Contribution to journal › Article
 
